Prevention of non-infectious panuveitis relapse in possible ocular sarcoidosis with fluocinolone acetonide (FAc, 0.19 mg, ILUVIEN®) implant: a case report
Fluocinolone acetonide (FAc, 0.19 mg, ILUVIEN®) intravitreal implant is approved for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The aim of this case report is to describe a case of panuveitis in possible ocular sarcoidosis treated with intravitreal implant of FAc.
Setting/Venue
Uveitis unit of the Ophthalmology department of Centro Hospitalar Universitário do Porto (CHUPorto)
Methods
Case-report of a 36 year-old female patient, with recurrent bilateral panuveitis treated with intravitreal FAc implant in the right eye (RE).
Results
A 36 year-old woman was referred to our department complaining of progressive vision loss secondary to bilateral panuveitis, diagnosed at least ten years before. At presentation, right eye (RE) best corrected visual acuity (BCVA) was “counting fingers” and left eye (LE) BCVA was 20/100. Biomicroscopy revealed active bilateral granulomatous anterior uveitis with 360º posterior synechiae and posterior subcapsular cataract (RE>LE). Both eyes fundoscopy was limited but LE macular edema was suspected. She underwent possible ophthalmic and systemic work-up. SD-OCT confirmed LE macular edema and systemic work-up was negative for systemic infectious and autoimmune diseases. In addition to topical medication, she started systemic steroids and azathioprine and thereafter adalimumab, with improvement of LE macular edema and intraocular inflammation control bilaterally. Ten months after presentation, RE cataract surgery was performed. Four months after surgery, bilateral granulomatous anterior uveitis was noticed with vitreous haze 1+, snowballs and macular edema in the RE. The patient was treated with intravitreal dexamethasone implant (Ozurdex®) in the RE and subtenon triamcinolone injection in the LE, with prompt decrease of intraocular inflammation and macular edema. Eight months after Ozurdex®, intravitreal Fac implant (ILUVIEN®) was injected in the RE with long-term control of inflammation for at least one year.
Conlusions
This case report suggests that FAc implant is useful in the prevention of non-infectious uveitis relapses, including panuveitis, allowing a sustained long-term control of intraocular inflammation and associated uveitic macular edema .